

A Short Communication on Pharmacokinetic Parameters of Vancomycin used in Severe Infections in Children

Bo Zhou^{1,3,4,5}, Yan Zhou^{1,3,4,5}, Yue-Qiang Fu^{2,3,4,5}, Jing Li^{2,3,4,5}, Chengjun Liu^{2,3,4,5*}, Wenhui Lv⁶

¹Department of Pharmacy, Children's Hospital of Chongqing Medical University, Chongqing, China

²Department of Critical Care Medicine, Children's Hospital of Chongqing Medical University, Chongqing, China

³Department of Child Nutrition and Health, National Clinical Research Center for Child Health and Disorders, Chongqing, China

⁴Department of Child Nutrition and Health, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China

⁵Department of Pediatrics, Chongqing Key Laboratory of Pediatrics, Chongqing, China

⁶Department of Pharmacy, Yunyang County Women and Children's Hospital, Yunyang Chongqing, China

Short Communication

Received: 16-Feb-2023, Manuscript No. JPPS-23-89457; **Editor assigned:** 20-Feb-2023, Pre QC No. JPPS-23-89457 (PQ); **Reviewed:** 06-Mar-2023, QC No. JPPS-23-89457; **Revised:** 13-Mar-2023, Manuscript No. JPPS-23-89457 (R); **Published:** 20-Mar-2023, DOI: 10.4172/2320-1215.12.1.002

***For Correspondence:**

Chengjun Liu, Department of Critical Care Medicine, Children's Hospital of Chongqing Medical University, Chongqing, China

E-mail: liucwd@163.com

Citation: Liu C, et al. A Short Communication on Pharmacokinetic Parameters of Vancomycin used in Severe Infections in Children.

RRJ Pharm Pharm Sci. 2023;12:002

Copyright: © 2023 Zhou B, et al. This is an open-access article distributed

ABSTRACT

Infectious diseases are one of the main diseases in children, and Gram-Positive Bacteria (GPB) infection is an important part of them. For the treatment of GPB, vancomycin is our "last line of defense". By monitoring and calculating the pharmacokinetic parameters of vancomycin and formulating individualized vancomycin administration regimen, it plays a very important role in improving the outcome of GPB infection in children. The current article reviews the application of vancomycin pharmacokinetic parameters in severe infections in children.

Keyword: Vancomycin; Pharmacokinetic; Therapeutic drug monitoring; Children

under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

INTRODUCTION

Vancomycin is one of the primary agents for the treatment of severe infections caused by GPB, particularly against drug-resistant Gram-positive bacteria, including Methicillin-Resistant Staphylococcus Aureus (MRSA). Given the safety factors of this class of special use antibiotics and the changing levels of liver and kidney function as children grow and develop, Therapeutic Drug Monitoring (TDM) is very important for us, and combine the monitoring results and its original pharmacokinetic parameters to develop an individualized vancomycin anti-infection program for patients, so as to ensure the safety and effectiveness of clinical treatment [1].

The samples used for vancomycin TDM are serum or plasma. It is recommended to take samples to monitor valley concentration 30 minutes before the fourth dose of medication, and 0.5-1 hours after the end of medication to monitor peak concentration [2]. For patients with continuous medication, TDM can be performed weekly according to the needs of the condition, while for children with hemodynamic instability, high-dose medication, and renal dysfunction, TDM should be performed more times [3,4].

VANCOMYCIN TDM IN PEDIATRIC PATIENTS

The biggest difference between children and adults is that children are in the stage of continuous growth and development, which will result in the pharmacokinetic parameters of vancomycin in children are different from those of adults, and there are even large differences in children of different ages [5]. This will lead to the possibility of large individual differences in the treatment of vancomycin in children with severe infections. Therefore, the need for therapeutic drug monitoring of vancomycin is higher in children than in adults, especially in neonates, obesity, burns, concomitant use of renal damage drugs (such as aminoglycosides, amphotericin B, etc.), admission to PICUs, or concomitant Continuous Renal Replacement Therapy(CRRT) treatment. We should consider routine monitoring of vancomycin for these exceptional children [6].

THE VALLEY CONCENTRATION OF VANCOMYCIN

Steady-state valley concentration is a classical pharmacokinetic parameter to evaluate the efficacy and safety of all drugs, especially for antibiotics such as vancomycin. Previous studies have shown that for adult patients, the valley concentration of vancomycin can be maintained at 10~15 mg/L or 10~20 mg/L according to the severity of infection. For neonates or children, maintaining vancomycin valley concentration at 5-15 mg /L is likely to produce better efficacy and minimize adverse drug events [7]. However, the pharmacokinetics (PK) and pharmacodynamics (PD) characteristics of vancomycin in children may be different from those of adults. Therefore, no matter how TDM is performed in children or what the outcome of TDM is, each should be analyzed separately. This is also one of the reasons why some children with vancomycin are still effective in clinical treatment when the steady-state valley concentration of vancomycin is less than 10 mg/L[8]. If the dosage is blindly increased at this time, it will bring additional risk of renal toxicity [9]. Therefore, the new version of TDM guideline of Vancomycin Pharmacist published by American Society of Health-System Pharmacist (ASHP) in 2020 no longer recommended monitoring vancomycin

valley concentration, but recommended monitoring the area under the curve (AUC_{0~24 h}) level of vancomycin more [10].

MONITORING AUC_{0~24 H} OF VANCOMYCIN

Different from monitoring valley concentration, monitoring vancomycin AUC_{0~24 h} will more accurately and objectively show the degree of drug absorption and utilization, which is an important parameter for evaluating drug bioavailability and bioequivalence? Currently, the AUC_{0~24 h} of vancomycin can be mainly calculated by Bayesian estimation method or primary pharmacokinetic formula. Based on the high proportion of minimum inhibitory concentration (MIC) ≤ 1 mg/L of vancomycin against MRSA and other pathogens, a number of studies have suggested that the target range of vancomycin AUC_{0~24 h} should be set at 400~650 mg·h·L⁻¹ (the results of systematic evaluation show that AUC_{0~24 h}/MIC > 400 correlated with the efficacy of vancomycin treatment, AUC_{0~24 h} > 650 mg·h·L⁻¹ is associated with a higher risk of renal toxicity), but more solid evidence is needed to confirm these recommendations in neonatal or pediatric patients [10]. We have previously discussed that it may be an appropriate threshold for predicting vancomycin-related nephrotoxicity that AUC_{0~24 h} > 537.18 mg·h·L⁻¹ [11]. For patients with abnormal renal function, the monitoring of vancomycin AUC_{0~24 h} is not fully applicable, and a comprehensive analysis should be made based on the valley concentration level [12].

REPEAT TDM

If the dose of the patient is adjusted according to valley concentration or AUC_{0~24 h} after the initial TDM, it is recommended to repeat the TDM at 4~5 doses after the dose adjustment, because the blood concentration of vancomycin in the new regimen has reached a new stable state at this time. In addition, patients admitted to PICU, receiving vasoactive agents, or receiving renal replacement therapy often have hemodynamic instability, which may lead to large individual differences in vancomycin PK characteristics, and these patients should repeat TDM. For severe infections, more intensive TDM can ensure that the PK/PD target is consistently reached during treatment [13].

VANCOMYCIN INDIVIDUALIZED ADMINISTRATION REGIMEN BASED ON PK/PD

No matter monitoring vancomycin valley concentration or AUC_{0~24 h}, after the implementation of TDM, using Bayesian estimation method, two-point method or one-point method to individually design subsequent vancomycin administration scheme is currently considered the most appropriate vancomycin administration adjustment method [14]. In addition to dose adjustment after TDM, the combination of population pharmacokinetic model and Bayesian estimation method can also be used to assist the initial measurement design. Continuous optimization of PK based vancomycin individualized administration regimen can improve the standard rate of blood drug concentration, indicating the risk of renal toxicity in patients to a certain extent, but its correlation with clinical efficacy needs to be confirmed by further studies [15].

RESULTS OF APPLICATION OF VANCOMYCIN PHARMACOKINETIC PARAMETERS IN CHILDREN

By monitoring the pharmacokinetic parameters of vancomycin, more and more studies recommend loading dose of the first dose for patients with substandard blood concentration in addition to increasing the dose and extending the infusion time. Compared with the no-load dose group, this method can significantly increase the standard rate of vancomycin concentration without increasing the risk of renal toxicity (adult single dose 25-30 mg/kg, children single dose 30 mg/kg) [16]. In addition, for children, the initial dose of 60 mg·kg⁻¹·d⁻¹ is not enough to guarantee the standard blood concentration level. Especially for children aged 1-6 years, the risk of low blood concentration may be higher, and the dosage of more than 60 mg·kg⁻¹·d⁻¹ may be considered when necessary. Consideration of

the risk of renal toxicity at high doses of vancomycin should be accompanied by consideration of the need to switch to other antimicrobial agents ^[17].

DISCUSSION

For children with severe infection, valley concentration and AUC_{0~24 h} are the main pharmacokinetic parameters currently monitored during vancomycin treatment, and whether these two indicators reach the standard or not will predict the effectiveness and safety of treatment to a certain extent ^[18]. It is feasible to monitor valley concentration by TDM, but its predictive significance may vary greatly among children. AUC_{0~24 h} > 537.18 mg•h•L⁻¹ may be an appropriate threshold for predicting vancomycin-related nephrotoxicity in children, but for children, whether 400~650 mg•h•L⁻¹, the target value of AUC_{0~24 h}, is related to clinical efficacy needs to be further studied ^[11,19].

CONCLUSION

This article reviews the monitoring of vancomycin in the treatment of severe infection in children and the application of pharmacokinetic parameters. AUC_{0~24 h} and valley concentration were associated with safety and efficacy in children treated with vancomycin, respectively. For children patients, hospitals with conditions can consider AUC_{0~24 h} monitoring for children with normal renal function, which will ensure the drug safety of vancomycin to a greater extent. Hospitals that cannot carry out AUC_{0~24 h} monitoring can monitor vancomycin valley concentration and guide further adjustment of drug use plan.

FUNDING

This project was supported by the National Clinical Research Center for Child Health and Disease, Clinical Medicine Research General Program (Item no. NCRCCHD-2020-GP-0X to CL), the Chongqing Science and Health Joint Medical Scientific Research Project (Item no. 2022ZDXM022 to CL). The open access publication fees come from the above two funds.

AUTHOR'S DECLARATION

All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

REFERENCES

1. Aljefri DM, et al. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis. 2019;69:1881-1887.
2. Neil JCM, et al. Vancomycin therapeutic drug monitoring in children: new recommendations, similar challenges. J Pediatr Pharmacol Ther. 2020;25:472-475.
3. Olson J, et al. Intravenous vancomycin therapeutic drug monitoring in children: evaluation of a pharmacy-driven protocol and collaborative practice agreement. J Pediatr Infect Dis. 2020;9:334-341.
4. Patel J, et al. Vancomycin therapeutic drug monitoring in paediatrics. J Paediatr Child Health. 2020;56:563-570.
5. Chen J, et al. The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients. Pharmacol Res Perspect. 2021;9:885.

6. Alsultan A, et al. Optimizing vancomycin monitoring in pediatric patients. *Pediatric Infect Dis J*. 2018;37:880-885.
7. Rybak MJ, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm*. 2020;77:835-864.
8. Kondo M, et al. Association of initial trough concentrations of vancomycin with outcomes in pediatric patients with gram-positive bacterial infection. *Biol Pharm Bull*. 2020;43:1463-1468.
9. Kwak S, et al. Vancomycin-induced nephrotoxicity in non-intensive care unit pediatric patients. *Sci Rep*. 2021;11:20681.
10. He N, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese Pharmacological Society. *Clin Infect Dis*. 2020;71:S363-S371.
11. Zhou B, et al. Clinical application value of pharmacokinetic parameters of vancomycin in children treated in the pediatric intensive care unit. *Front Pediatr*. 2022;10:867712.
12. Aljefri DM, et al. Vancomycin area under the curve and acute kidney injury: a meta-analysis. *Clin Infect Dis*. 2019;69:1881-1887.
13. Liang X, et al. A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring. *Clin Infect Dis*. 2018;67:S249-S255.
14. Meng L, et al. Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an academic medical center. *Pharmacotherapy* 2019;39:433-442.
15. Neely MN, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. *Antimicrob Agents Chemother* 2018;62:17.
16. Finch NA, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. *Antimicrob Agents Chemother*. 2017;61:17.
17. Tkachuk S, et al. The relationship between vancomycin trough concentrations and AUC/MIC ratios in pediatric patients: a qualitative systematic review. *Paediatr Drugs*. 2018;20:153-164.
18. Yoo R, et al. Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant *Staphylococcus aureus* bacteremia in children. *PLoS One*. 2021;16.
19. Feiten HDS, et al. Vancomycin-associated nephrotoxicity and risk factors in critically ill children without preexisting renal injury. *Pediatr Infect Dis J*. 2019;38:934-938.